Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma

Ähnliche Einträge

• Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study
  von: Wen‐Jin Zhong, et al.
  Veröffentlicht: (2024)
• Patterns of recurrence after curative resection and adjuvant chemotherapy in gastric and gastroesophageal junction cancer
  von: Chengzhi Wei, et al.
  Veröffentlicht: (2026)
• Whole‐transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential
  von: Tadayoshi Hashimoto, et al.
  Veröffentlicht: (2024)
• Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
  von: Michael Masetti, et al.
  Veröffentlicht: (2024)
• Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
  von: Li Chao, et al.
  Veröffentlicht: (2024)